Richtlijn Diabetische nefropathie (2006) - Kwaliteitskoepel

R i s i c o f a c t o r e n e n m o g e l i j k h e d e n v o o r p r e v e n t i eNiveau 3Bij T2DM heeft een ACE-remmer voordelen ten opzichte van een calciumantagonistbij het verminderen van de kans op het optreden van eenmyocardinfarct.A2: Estacio 1998 8Literatuur1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes onthe development and progression of long-term complications in insulin-dependent diabetes mellitus. New EnglJ Med 1993;329:977-86.2. UK Prospective Diabetes Study Group. 231 Intensive blood-glucose control with sulphonylureas or insulincompared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet 1998;352:837-53.3. Tuominen JA, Ebeling P, Koivisto VA. Long-term lisinopril therapy reduces exercise-induced albuminuria innormoalbuminuric normotensive IDDM patients. Diabetes Care 1998;21:1345-8.4. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuricpatients with type 1 diabetes mellitus. QJM 2001;94:89-94.5. [No authors listed] Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependentdiabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349:1787-92.6. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular andmicrovascular complications in type 2 diabetes: (UKPDS 38). BMJ 1998;317:703-13.7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascularoutcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.8. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascularoutcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.9. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptorantagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-39.10. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane DatabaseSyst Rev 2005;(4):CD004136.41